Research programme: antiviral therapeutics - Lead Discovery Siena
Latest Information Update: 28 Oct 2022
At a glance
- Originator University of Siena
- Developer Lead Discovery Siena
- Class Antivirals; Small molecules
- Mechanism of Action DEAD-box RNA helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Viral infections
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Viral-infections in Italy
- 05 Sep 2018 Antiviral therapeutics - Lead Discovery Siena is available for licensing as of 05 Sep 2018. http://leaddiscoverysiena.it/ (Lead Discovery Siena website, September 2018)
- 05 Sep 2018 Preclinical trials in Viral infections in Italy (unspecified route) (Lead Discovery Siena website, September 2018)